Identifying Effective Durations of Antibiotic Therapy for the Treatment of Carbapenem-resistant Enterobacterales Bloodstream Infections: A Multicenter Observational Study.

Publication date: Jan 25, 2024

In a propensity-score-weighted cohort of 183 adults with carbapenem-resistant Enterobacterales bacteremia at 24 US hospitals, patients receiving short courses of active therapy (7-10 days, median 9 days) experienced similar odds of recurrent bacteremia or death within 30 days as those receiving prolonged courses of active therapy (14-21 days, median 14 days).

Concepts Keywords
Antibiotic bacteremia
Death carbapenem-resistant Enterobacterales
Enterobacterales ceftazidime-avibactam
Hospitals meropenem-vaborbactam


Type Source Name
disease VO effective
disease MESH Bloodstream Infections
disease MESH bacteremia
disease MESH death
drug DRUGBANK Ceftazidime
drug DRUGBANK Avibactam
drug DRUGBANK Meropenem
drug DRUGBANK Vaborbactam

Original Article

(Visited 1 times, 1 visits today)